Rate My Professor Anna Lok

Dr. Lok's academic interests center on the epidemiology, natural history, and treatment of chronic hepatitis B and C, risk stratification in nonalcoholic fatty liver disease, and the prevention and early detection of hepatocellular carcinoma. Her research receives funding from the National Institutes of Health, federal and private foundations, and pharmaceutical companies. She has authored over 600 publications on viral hepatitis and liver diseases, co-authoring five editions of the American Association for the Study of Liver Diseases Practice Guidelines on Chronic Hepatitis B, including the influential 2018 update. Prominent works include "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance" (Hepatology, 2018), "EASL 2012 clinical practice guidelines: Management of chronic hepatitis B virus infection" (Journal of Hepatology, 2012), and "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B" (New England Journal of Medicine, 2006). Ranked among the top 1% most cited scientists worldwide for 2002-2012, she has mentored over 60 fellows and junior faculty from around the world. Dr. Lok was President of the American Association for the Study of Liver Diseases in 2017, elected to the National Academy of Medicine in 2022, and has earned awards such as the Distinguished Scientific Achievement Award from the American Liver Foundation (2015), William Beaumont Prize in Gastroenterology from the American Gastroenterological Association (2016), and International Recognition Award from the European Association for the Study of the Liver (2018). She serves as Associate Editor of Hepatology Communications and has held prior editorial positions with Hepatology, Journal of Viral Hepatitis, and Gastroenterology.